Real-World Evaluation of the Safety and Efficacy of Surgi-ORC® in Orthopedic Surgeries: A Multicenter Prospective Study

Aim Achieving adequate hemostasis is a critical aspect of surgical practice, especially in orthopedics, where bleeding can impact visibility and patient outcomes. Surgi-ORC® (Aegis Lifesciences Pvt. Ltd., Ahmedabad, India), an oxidized regenerated cellulose hemostatic agent, was evaluated for its safety, efficacy, biocompatibility, and clinical performance in real-world patients undergoing orthopedic surgeries. Method This prospective observational study included patients undergoing upper limb, lower limb, or axial skeletal orthopedic surgeries. Blood loss, time to hemostasis (TTH), and surgeon-rated performance parameters such as ease of application, conformation to tissue, and preparation were recorded to assess the performance of Surgi-ORC® at predefined time points. Biocompatibility assessments were conducted through in vitro and in vivo tests, including reactivity, sensitization, systemic toxicity, tissue response, and hemolytic potential. Results The study involved 59 patients undergoing orthopedic surgeries using Surgi-ORC® variants: Powder (n=4), Knit (n=5), Original/Standard (n=4), Fibril (n=42), and Non-Woven/Snow (n=4). Hemostasis was achieved in 100% of cases within ≤ five minutes, with a mean TTH of 1.95 minutes (Surgi-ORC® Original/Standard). Powder demonstrated the lowest mean TTH across all surgeries, averaging 0.83 to 1.08 minutes. Surgeon feedback highlighted excellent handling, ease of application, and conformance to tissue without sticking/adherence to surgical gloves/surgical instruments. No infections, adverse events, or complications occurred over 60 days, and all patients showed stable recoveries. The surgeon confirmed complete absorption by day two. Conclusion Surgi-ORC® is a reliable and effective hemostatic agent for orthopedic surgeries. Its ease of use, handling characteristics, ease of placing, stability upon placement, and safety profile make it a preferred choice among surgeons.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-02-06
DOI
https://doi.org/10.7759/cureus.78616
Citations
1
Primary Topic
Cardiac, Anesthesia and Surgical Outcomes
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Evaluation of the Safety and Efficacy of Surgi-ORC® in Orthopedic Surgeries: A Multicenter Prospective Study

Diksha Sharma, Piyush Patel, Bhavin Trivedi, Shahid Karatela
1 citations
Cureus
Cardiac, Anesthesia and Surgical Outcomes
1.39
article

Real-World Evaluation of the Safety and Efficacy of Surgi-ORC® in Orthopedic Surgeries: A Multicenter Prospective Study

Diksha Sharma, Piyush Patel, Bhavin Trivedi, Shahid Karatela
article en
1 citations

Abstract

Aim Achieving adequate hemostasis is a critical aspect of surgical practice, especially in orthopedics, where bleeding can impact visibility and patient outcomes. Surgi-ORC® (Aegis Lifesciences Pvt. Ltd., Ahmedabad, India), an oxidized regenerated cellulose hemostatic agent, was evaluated for its safety, efficacy, biocompatibility, and clinical performance in real-world patients undergoing orthopedic surgeries. Method This prospective observational study included patients undergoing upper limb, lower limb, or axial skeletal orthopedic surgeries. Blood loss, time to hemostasis (TTH), and surgeon-rated performance parameters such as ease of application, conformation to tissue, and preparation were recorded to assess the performance of Surgi-ORC® at predefined time points. Biocompatibility assessments were conducted through in vitro and in vivo tests, including reactivity, sensitization, systemic toxicity, tissue response, and hemolytic potential. Results The study involved 59 patients undergoing orthopedic surgeries using Surgi-ORC® variants: Powder (n=4), Knit (n=5), Original/Standard (n=4), Fibril (n=42), and Non-Woven/Snow (n=4). Hemostasis was achieved in 100% of cases within ≤ five minutes, with a mean TTH of 1.95 minutes (Surgi-ORC® Original/Standard). Powder demonstrated the lowest mean TTH across all surgeries, averaging 0.83 to 1.08 minutes. Surgeon feedback highlighted excellent handling, ease of application, and conformance to tissue without sticking/adherence to surgical gloves/surgical instruments. No infections, adverse events, or complications occurred over 60 days, and all patients showed stable recoveries. The surgeon confirmed complete absorption by day two. Conclusion Surgi-ORC® is a reliable and effective hemostatic agent for orthopedic surgeries. Its ease of use, handling characteristics, ease of placing, stability upon placement, and safety profile make it a preferred choice among surgeons.

CureusVol. 17(2)
Bioscience Research (US), Ahmedabad University (IN), Indus University (IN)
Openalex Percentile: Top 23%
Cardiac, Anesthesia and Surgical Outcomes
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.